Verona pharma to present additional analyses of positive phase 3 enhance studies in copd at ats 2024

Pdufa target action date of june 26, 2024 eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of pde3 and pde4 london and raleigh, n.c., may 02, 2024 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), announces eight posters, including two mini oral symposia, on additional analyses from its successful phase 3 enhance studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“copd”) will be presented at the american thoracic society international conference (“ats”) 2024.
VRNA Ratings Summary
VRNA Quant Ranking